10-K/A: InMed Pharma Amends 10-K, Details Governance & Pay

Sentiment:

Amendment to Annual Report 24 October 2025 4:05 PM

📋All filings for Inmed Pharmaceuticals INC

InMed Pharmaceuticals Inc. filed an amendment to its annual report, providing detailed disclosures on executive compensation, corporate governance, and director independence for the fiscal year ended June 30, 2025.

Delay expectedThe company is filing this Amendment No. 1 on Form 10-K/A because it will not file a definitive proxy statement containing the required Part III information within 120 days after the end of the fiscal year ended June 30, 2025.

Capital raiseThe company's financial position, including its ability to raise additional capital, is a key factor in determining the payment of cash bonuses to employees.The definition of 'Change in Control' in executive employment agreements includes 'another capital raising event'.Sabby Volatility Warrant Master Fund, Ltd. holds pre-funded warrants and preferred investment options, indicating past capital raises or potential future exercises of these securities.Armistice Capital Master Fund Ltd. beneficially owned preferred investment options entitling them to acquire common shares.

Summary

This Amendment No. 1 on Form 10-K/A was filed to include previously omitted Items 10, 11, 12, 13, and 14 of Part III from the original Form 10-K for the fiscal year ended June 30, 2025.
The company is filing this amendment because it will not file a definitive proxy statement containing the required information within 120 days after the fiscal year-end.
New certifications from the principal executive officer and principal financial officer are included as exhibits.
Detailed information on the Board of Directors, executive officers, their biographies, and committee memberships is provided.
The filing outlines the company's executive and director compensation policies, including base salaries, annual performance-based cash bonuses, and equity-based awards.
Security ownership of certain beneficial owners and management, along with related stockholder matters, is disclosed.
Information regarding related party transactions and director independence is presented.
Audit and tax fees paid to the company's independent registered public accounting firms for fiscal years 2025 and 2024 are detailed.

Sentiment

Score: 6

Explanation: The filing provides necessary transparency on corporate governance and executive compensation, which is positive for investor confidence. The compensation structure, with its emphasis on equity, aligns management incentives with shareholder value creation. However, the procedural delay in filing Part III information and the substantial audit fees are minor concerns.

Positives

The Board of Directors includes independent members, and Mr. Bryan Baldasare has been determined to be an audit committee financial expert.
Established Audit, Compensation, and Governance & Nomination Committees operate under written charters with independent members, ensuring robust oversight.
The company has adopted an Insider Trading Policy and an Anti-Hedging Policy to promote compliance with securities laws and align executive interests with shareholders.
The compensation program is designed to attract and retain qualified executives, incentivize strong business performance, and align executive interests with shareholders through significant equity-based compensation, targeting the 50th percentile of benchmark data.
A clawback policy is in place for incentive compensation, allowing recovery or forfeiture in the event of financial restatements.
Board oversight, including annual approval of budgets, frequent discussions with management, and review of business opportunities, helps mitigate risks.

Negatives

The company failed to file its definitive proxy statement within 120 days after the fiscal year-end, necessitating this 10-K/A amendment.
Total audit fees for fiscal year 2025 were $408,000, which is substantial for a pre-commercial biopharmaceutical company.
Cash compensation (salaries plus bonus) is currently targeted around the 25th percentile of industry benchmarks, which, while conserving cash, might pose challenges in attracting top-tier talent if not adequately offset by equity.

Risks

The Compensation Committee did not identify any significant risks arising from the company's executive compensation programs that are reasonably likely to have a material adverse effect on the company in fiscal year 2025.
The Board's active involvement at the strategic level, including annual approval of operational and capital budgets, frequent discussions with management, and approval of business opportunities, helps to ensure proper monitoring of the level of risk-taking by management.

Future Outlook

The company aims to grow its business long-term and intends to move executive base salaries towards the 25th percentile of industry benchmarks over time, while maintaining equity-based compensation at the 50th percentile to align executive interests with long-term shareholder value.

Management Comments

"Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report." (Paraphrased from certifications by Eric A. Adams, President and Chief Executive Officer, and Netta Jagpal, Chief Financial Officer)

Industry Context

As a biopharmaceutical company, InMed operates in a highly competitive industry for executive talent. Its compensation strategy reflects this by aiming for competitive total compensation, with a strong emphasis on equity-based awards to align executive interests with long-term shareholder value, a common practice in pre-commercial biotech firms where cash conservation for R&D is critical.

Comparison to Industry Standards

The company utilized an AON/Radford compensation assessment in 2023 to benchmark its compensation practices.
The assessment included data from US and Canadian public, pre-commercial, and commercial biopharmaceutical companies with under 60 employees, less than $75 million in revenues, and market capitalization less than $150 million.
Cash compensation (salaries plus bonus) is targeted around the 25th percentile of this benchmark data set.
Equity-based compensation is targeted around the 50th percentile of this benchmark data set.
This compensation strategy is designed to conserve cash for R&D programs while strongly aligning executive interests with those of shareholders.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Director	Janet Grove		February 10, 2025	Resignation, accepted by the Board upon recommendation of the Governance and Nomination Committee.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Committee Establishment and Operation	The Board has established an Audit Committee, a Compensation Committee, and a Governance and Nomination Committee, each operating pursuant to a written charter.	N/A	Enhances corporate oversight and compliance with applicable regulations.
Director Independence	The Board has determined that all directors, except for the CEO Eric A. Adams, are independent as defined under applicable SEC and Nasdaq rules and Canadian securities laws.	N/A	Ensures independent judgment in board decisions and strengthens governance.
Audit Committee Financial Expert	The Board has determined that Mr. Bryan Baldasare is an audit committee financial expert.	N/A	Provides specialized financial expertise to the Audit Committee, improving financial reporting oversight.
Policy Adoption	The Board has adopted an Insider Trading Policy and an Anti-Hedging Policy.	N/A	Promotes compliance with insider trading laws and aligns the interests of directors and executives with shareholders by prohibiting hedging against equity value declines.
Code of Conduct	The Governance and Nomination Committee periodically reviews and assesses the adequacy of the company's Code of Conduct.	N/A	Ensures ethical behavior and professional standards across the company.
Clawback Policy	A clawback policy has been adopted, allowing the company to seek recovery or forfeiture of incentive compensation in the event of financial statement restatements under certain circumstances.	N/A	Increases accountability for executive officers and other employees whose conduct contributes to restatements.
Related Person Transaction Policy	The company has adopted a written policy requiring Board or Audit Committee approval or ratification for related person transactions exceeding $120,000.	N/A	Ensures transparency and fairness in dealings with related parties, protecting shareholder interests.
Auditor Pre-Approval Policy	The Audit Committee must review and approve, in advance, the scope and plans for audits and audit fees, and approve in advance all permissible non-audit and tax services.	N/A	Maintains auditor independence and ensures appropriate oversight of audit and non-audit services.

Related Party Transactions

Norton Rose Fulbright Canada LLP (NRFC) and Norton Rose Fulbright US LLP (NRF) rendered legal services to the company.
Janet Grove, a director from February 11, 2022, until her resignation on February 10, 2025, was a partner of NRFC.
Fees for legal services from NRF totaled $316,977 for the period from July 1, 2024, to February 10, 2025.
Fees for legal services from NRF totaled $226,793 for the twelve months ended June 30, 2024.
No legal services were directly provided by Ms. Grove.
These transactions were in the company's normal course of operations and were measured at the exchange amount.

Stakeholder Impact

Shareholders: Benefit from increased transparency in corporate governance and executive compensation, with compensation structures designed to align management incentives with long-term shareholder value.
Employees: The compensation program aims to attract and retain qualified talent, offering competitive packages including extended health insurance and expense reimbursements.
Management: Compensation is structured to incentivize strong performance and align with corporate objectives, with a significant portion tied to equity.
Regulatory Authorities: The filing demonstrates compliance with SEC reporting requirements, albeit with a delay in the initial 10-K filing for Part III information.

Next Steps

The Compensation Committee will annually develop a calendar of activities or forward agenda to be undertaken for each ensuing year.
The Compensation Committee will report to the Board at its next regular meeting all actions taken since the previous report.
The company will post amendments to the Code of Conduct or waivers for directors and executive officers on its website.

Key Dates

Date	Description
June 16, 2016	Eric A. Adams became President & CEO and Director of the company.
September 12, 2016	Andrew Hull became a director of the company.
March 24, 2017	Shareholders approved the company's 2017 Amended Stock Option Plan.
March 8, 2018	Eric Hsu's initial employment agreement became effective.
September 20, 2018	Michael Woudenberg's initial employment agreement became effective.
November 20, 2020	The Stock Option Plan was amended.
February 11, 2022	Janet Grove was appointed as a director of the company.
May 12, 2022	Bryan Baldasare became a director of the company.
August 8, 2022	Nicole Lemerond became a director of the company.
July 1, 2023	Annual base salaries for Eric A. Adams, Michael Woudenberg, and Eric Hsu were increased.
February 20, 2024	Netta Jagpal was appointed Chief Financial Officer and her initial employment agreement became effective.
June 30, 2024	Fiscal year ended.
July 1, 2024	Annual base salaries for Eric A. Adams, Michael Woudenberg, Eric Hsu, and Netta Jagpal were further increased.
October 1, 2024	Director annual retainers and committee participation fees were adjusted.
November 1, 2024	CBIZ CPAs P.C. acquired the attest business of Marcum LLP.
November 14, 2024	Schedule 13G/A was filed by Armistice Capital Master Fund Ltd.
December 18, 2024	The company filed a Form S-8 with the Securities and Exchange Commission.
December 31, 2024	Last business day of the company's most recently completed second fiscal quarter.
February 10, 2025	Janet Grove resigned as a director of the company.
June 30, 2025	Fiscal year ended.
September 17, 2025	Date for common shares outstanding count.
September 23, 2025	Original Annual Report on Form 10-K for the fiscal year ended June 30, 2025, was filed.
October 22, 2025	Date for beneficial ownership calculation.
October 24, 2025	Date of filing of this Amendment No. 1 on Form 10-K/A and certifications.

Recommendation

hold

The filing provides necessary transparency on corporate governance and executive compensation, which is a positive for investor confidence. The compensation structure, with its emphasis on equity, aligns management incentives with shareholder value creation. However, the procedural delay in filing Part III information and the substantial audit fees are minor concerns. Without new financial performance data or significant strategic announcements, the filing does not present a strong catalyst for a 'buy' or 'sell' recommendation, suggesting a 'hold' position for existing investors.

Keywords

INMED Pharmaceuticals, SEC filing, 10-K/A, Annual Report Amendment, Corporate Governance, Executive Compensation, Director Independence, Audit Committee, Compensation Committee, Biopharmaceutical, Nasdaq, Stock Options, Related Party Transactions, Financial Reporting, Risk Management

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.